DEEPVESSEL FFR is a software medical device that uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary computed tomography angiography (CCTA). The software processes coronary CTA images semi-automatically, generates a three-dimensional model of the coronary artery tree, and estimates CT FFR values. DEEPVESSEL FFR is FDA-Cleared, CE-Marked, NMPA-Cleared, HSA-Certified.

Keya Medical is an international medical technology company developing deep learning-based medical devices for disease diagnosis and treatment. The company is committed to creating solutions that deliver clinical value at all stages in the patient care process, covering specialties including cardiology, neurology, pulmonology, pathology, and surgery. Keya Medical has four centers in Beijing, Shanghai, Shenzhen, and Seattle. 

The deep-learning-based CT FFR analysis DEEPVESSEL FFR is the company's flagship product. The AI CT FFR is FDA-cleared, CE-marked, and NMPA-approved. DEEPVESSEL FFR is a software medical device that uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary computed tomography angiography (CCTA). 

ActX helps physicians make better decisions about medical treatment, using patients’ genetic information. ActX uses its GenoACT℠ clinical decision support program to analyze a patient’s genetic information and alert physicians in real time through their existing workflow tool, the electronic health record, about drug-genome interactions, actionable hereditary risks and carrier status

Deep Learning

Accurate

Fast

Comprehensive

Flexible Payment Model

Accessible

Deep Learning

Accurate

Fast

Comprehensive

Flexible Payment Model

Accessible

Please reach out to ActX for more information.

Please reach out to ActX for more information.